MedTrace Logo

Rheumatoid Arthritis DMARD Intervention and UtilizationStudy

NCT00116727 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5103

Last updated 2011-05-06

No results posted yet for this study

Summary

To systematically collect and document use patterns, effectiveness and safety of DMARD treatments currently used in the management of rheumatoid arthritis. The primary purpose of this study is to estimate the incidence of serious adverse experiences and adverse experiences of interest in patients with rheumatoid arthritis (RA) treated with ENBREL®.

Conditions

Interventions

DRUG

ENBREL®

50 mg/wk SC

Sponsors & Collaborators

  • Immunex Corporation

    collaborator INDUSTRY

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Amgen

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2008-06-30
Completion
2008-10-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116727 on ClinicalTrials.gov